Neuroblastoma stem cells – mechanisms of chemoresistance and histone deacetylase inhibitors

Minireview**

M. A. KHALIL1, J. HRABETA1, S. CIPRO1, M. STIBOROVA1, A. VICHA1, T. ECKSCHLAGER* 

1Department of Pediatric Hematology and Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol, V Uvalu 84, 150 06 Prague, Czech Republic; 2Department of Pathology and Molecular Medicine, 2nd Medical Faculty, Charles University and University Hospital Motol, Prague, Czech Republic; 3Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic

*Correspondence: tomas.eckschlager@lfmotol.cuni.cz

Received April 1, 2012 / Accepted July 5, 2012

Cancer stem cells (CSCs) form a small proportion of tumor cells that have stem cell properties: self-renewal capacity, the ability to develop into different lineages and proliferative potential. The interest in CSCs emerged from their expected role in initiation, progression and recurrence of many tumors. They are generally resistant to conventional chemotherapy and radiotherapy. There are two hypotheses about their origin: The first assumes that CSCs may arise from normal stem cells, and the second supposes that differentiated cells acquire the properties of CSCs. Both hypotheses are not mutually exclusive, as it is possible that CSCs have a diverse origin in different tumors. CD133+ cells (CD133 is marker of CSC in some tumors) isolated from NBL, osteosarcoma and Ewing sarcoma cell lines are resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones. Being resistant to chemotherapy, there were many attempts to target CSCs epigenetically including the use of histone deacetylase inhibitors. The diverse influence of valproic acid (histone deacetylase inhibitor) on normal and cancer stem cells was proved in different experiments. We have found an increase percentage of CD133+ NBL cells after their incubation with VPA in a dose that does not induce apoptosis. Further researches on CSCs and clinical application for their detection are necessary: (i) to define the CSC function in carcinogenesis, cancer development and their role in metastasis; (ii) to find a specific marker for CSCs in different tumors; (iii) to explain the role of different pathways that determine their behavior and (iv) to explain mechanisms of chemoresistance of CSCs.

Key words: Cancer stem cells, CD133, Neuroblastoma, Histone deacetylase inhibitors

Cancer stem cells (CSCs) form a small proportion of tumor cells that have stem cell properties such as self-renewal capacity, the ability to develop into different lineages and proliferative potential [1, 2]. The interest in CSCs emerged from their expected role in initiation and maintenance of the tumor. Moreover they are supposed to be responsible for resistance to chemotherapy, radiotherapy and early recurrence in many tumors. Its prevalence in solid tumors is higher than that in leukaemia. It shows a variability between different types of tumors and even between tumors of the same type [3], see Fig. 1. CSCs are characterized by two basic properties: (i) efficiency to initiate cancer and control its proliferation therefore they are sometimes called “tumor initiating cells”; (ii) asymmetrical self-renewing cell division that gives rise to one identical copy of original CSC, and other cancer cell that is more differentiated. Asymmetric division is controlled by extracellular microenvironment, so called “stem cell niche” that supports CSCs growth and regulates their fate [4]. In metastatic process, cells must move out from the original tumor, migrate through blood or lymph, invade into a new

**Presented on the XX. Biological Days – Stem cells – from regenerative medicine to cancer, Pilsen, October 25-27, 2011
destiny, form micrometastases and develop a new blood supply [5]. Recently, it has been assumed that tumor metastases have their origin directly from CSCs [3]. This assumption is augmented by the finding that VEGF overexpression was detected in CD133+ glioblastoma cells which are located near tumor vessels in experimental tumors, suggesting that CSCs promote local angiogenesis [6].

The origin of CSCs is still a matter of discussion. There are two hypotheses about their origin: The first supposes that CSCs may arise from normal stem cells as they are more susceptible to accumulate oncogenic mutations due to their long life span, and the second supposes that differentiated cells acquire the properties of CSCs [2]. Both hypotheses are not mutually exclusive, as it is possible that CSCs have a diverse origin in different tumors.

Malignant tissue is not homogeneous, because it is composed of various cell populations. This heterogeneity is explained by CSC hypothesis which assumes that tumors are arranged hierarchically and the subpopulation of CSCs is responsible for maintainence of cancer growth [3]. Current chemo- and radiotherapy are based on the traditional tumor model which assumes that malignant cell develops from a mature somatic cell in which multiple genetic changes have occurred and thus acquires self-renewal and multilineage potency. According to the CSC hypothesis a different therapeutic strategy focused mainly on CSCs is required. The CSC hypothesis also enables to explain phenomenon of a minimal residual disease. Even a single CSC that evades the therapies by acquiring resistance recapitulates the whole tumorigenesis resulting in a relapse after complete clinical remission [7].

CSCs may be influenced by environmental conditions. Glioblastoma cell lines cultivated in normoxic conditions (21%O₂) have very low expression of CD133+ cells (marker of CSC in brain and some other tumors see below). The expression of CD133 increases in hypoxia (1%O₂) and maintained high as long as they are cultivated in hypoxic conditions while its percentage progressively decreased on exposure to normoxic condition again. CD133+ cells percentage was also found to increase by the decrease in mitochondrial membrane potential (∆Ψₘ) that is induced by rotenone [13]. The increase of CD133+ cells in hypoxia is probably due to increase in the expression of HIF-1α protein as its knockdown inhibits the hypoxia-mediated expansion of CD133+ tumor cells [14]. One may speculate that the increase in CSCs in hypoxia may participate in hypoxia-induced chemo- and radioresistance.

Colon cancer cell lines infected by Mycoplasma hyorhinis, one...
of the most common cell culture contaminants, had a higher percentage of CD133+ cells than the same mycoplasma-free lines. This phenomenon may be explained by resistance of CSCs to toxicity of mycoplasma or artificially by the influence of antibody binding [15].

**CSC detection.** CSCs may be defined by their tumorigenicity in vivo, but in practice they are usually detected by the presence or combination of various antigens such as CD24, CD44, CD133, aldehyde dehydrogenase (ALDH) activity and Hoechst efflux (so-called side population) in various malignant tumors. Side population has been defined by using the fluorescent dyes rhodamine 123 and Hoechst 33342 as cells that can rapidly efflux the Hoechst dye to produce a characteristic profile based on flow cytometric analysis. The side population phenotype is associated with high-level expression of the ATP-binding cassette transporter protein ABCG2/Bcrp1 [16]. The ATP-binding cassette (ABC) transporter superfamily contains membrane proteins that translocate a wide variety of substrates across extra- and intracellular membranes, including drugs. Overexpression of certain ABC transporters occurs in cancer cells that are multidrug resistant.

Cells expressing the above mentioned antigens can be isolated by fluorescence activated cell sorting (FACS) or by immunomagnetic separation [17]. Isolated CSCs have shown to be highly clonogenic, tumorigenic in vivo, and they can grow as spheres in serum-free media. Neurosphere assays are based on the cultivation of cancer cells from neuronal origin in selective serum-free media with growth factors (EGF, bFGF) and supplemented with B27, in which stem-like cells are able to divide continuously and form multipotent clonal spheres so-called neurospheres, while the more differentiated cells die under such conditions [18] (Fig. 2). It has been observed that isolated CD133+ cells grow as neurospheres and the CD133+ cell percentage correlates with the neurosphere-forming ability in glioblastomas cell lines. However, in single cell cultivation, the majority of CD133+ tumor cells were not able to form spheres. Similar correlation was noticed between neurospheres with side population and side population with CD133+ cells percentage. None of the three methods mentioned above is ideal for detection of CSCs. The population of cells defined by each of these methods represents heterogeneous populations which overlap each other [19]. The potential difficulties associated with each method complicate the interpretation of results. Therefore more sensitive and specific methods for detection of CSCs need to be developed.

There are several reports about the role of microRNA (miRNA) in regulation of CSCs. It represents a cluster of small non-coding RNA molecules consisting of 21–23 nucleotides that control the expression of specific genes at the post-transcriptional level. Their detection in cancer tissues or in serum may be used for improvement of diagnosis, prognosis determination or prediction of therapeutic efficiency. There is a hope that it will be possible to develop targeted therapy of miRNA directed against CSCs [20]. For example, it was found in neuroblastoma cell line SH-SY5Y that expression of miRNA-214 increased, whereas expression of miRNA-7 decreased during retinoic acid induced differentiation [21].

**CD133.** Yin et al. found that CD133 is expressed in part of CD34+ human hematopoetic stem cells [22]. It has been reported that CD133+/CD34+ cells had higher clonogenicity and an engraftment rate after experimental transplantation compared to CD133-/CD34+ cells [23]. Therefore, CD133 became another marker used for identification and separation of stem and precursor cells. Later, the CD133+ cells have been studied in different tissues, other than the hematological system, e.g. endothelial precursors cells, fetal brain stem cells, embryonic

---

Figure 2. Neuroblastoma cell line UKF-NB-3. Cultivated in serum-free medium consisting of: DMEM/F12 medium supplemented with bFGF, EGF, B-Mercaptoethanol, Heparin N2 and B27 supplements - left, Iscove's modified Dulbecco's medium (IMDM) with 10% serum - right. Neurospheres in serum free medium and attached growth in IMDM with serum. Olympus IX51, magnification 100x.
epithelial cells, prostate epithelial stem cells, progenitor cells with myogenic potential [24-28]. When CSCs were defined by their properties (self-renewal capacity, infinity of proliferation, differentiation potential and high oncogenicity), many groups found different CSC markers such as CD133, nestin, CD326 [29].

Initially, the CD133 cells were reported as a marker of CSCs in medulloblastoma and glioblastoma. Singh et al. screened out CD133+ cells from brain tumor using anti CD133 antibody and found that these cells had very strong capabilities of proliferation, self-renewal and differentiation [30]. Later, CD133 antigen was detected in CSCs of melanoma, pancreatic, colorectal, liver, prostate, renal, head and neck spinocelular, ovarian, and both small and non-small cell lung carcinomas [31-39]. Whereas the molecular structure of CD133 has already been characterized, the function of this molecule is still unknown. CD133 gene is located on chromosome 4p15.3-p15.2. Seven splice variants affecting the open reading frame in humans have been identified. Factors that regulate CD133 expression are not known, but the mRNA profile suggests that the splice variants are tissue specific and developmentally regulated [40]. The CD133 protein could be detected on a cell surface, and it is frequently intracellular with accumulations located in the endoplasmic reticulum and/or Golgi apparatus, but seemingly unrelated to particular CD133 splice variants or protein epitopes. In contrast, membrane-bound expression of CD133 was restricted to tumor cells bearing the extracellular CD133 epitope AC133 [41]. The CD133+ cells from different human tumors were more tumorigenic in immuno-deficient mice rather than the CD133− ones [42]. CD133+ cells from different cancers are chemoresistant and have been enriched in vivo after treatment with cisplatin, etoposide, doxorubicin, and paclitaxel [19, 43].

CD133+ cells from ovarian cancer and neuroblastoma had a greater S-phase fraction than CD133− cells [44, 45] see Fig. 3 This is in concordance with the report of Jaksch, who

![Figure 3. CD133+ cells in proliferative fraction (S+G2/M phase) and in G0/G1 phase. There was increased percentage of CD133+ cells in proliferative fraction compared with G0/G1 phase. Blue curve – isotypic control; red curve- anti-CD133 antibody.](image-url)
showed that the colon cancer, melanoma, and human embryonic stem cells with 4N DNA content had higher CD133 expression than the cells with 2N DNA [46]. Hence CD133 can be a proliferation marker, as well as a marker of tumor initiating cells.

**CSCs in Neuroblastoma (NBL).** NBL is the most common extracranial solid tumor in children and a major cause of neoplastic death in infancy. It originates from undifferentiated cells of the sympathetic nervous system. Based on its cellular and biological heterogeneity, NBL behavior can range from low-risk (LR) cancers with a tendency toward spontaneous regression or maturation, to high-risk (HR) ones with extensive growth, early metastasis and a poor prognosis [47]. Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy have been proposed as a stratifying prognostic markers in the International Neuroblastoma Risk Group classification system [48]. During the past 20 years, much effort has been directed towards the improvement of treatment results in HR NBL, but until now die more than 60% of children suffering from HR NBL. Intensive chemotherapy, including the introduction of high-dose chemotherapy with autologous stem cell transplantation and more recently maintenance therapy including differentiation agents and immunotherapy have contributed to further improvement. To improve the prognosis of children with HR NBL research has focused on the following areas: (1) improvement of earlier diagnosis of the disease; (2) studies to detect minimal residual disease; (3) attempts to influence the biology of the disease; (4) definition of new risk factors; (5) development of new therapeutic strategies; and (6) research of targeted therapy, such as 131I-MIBG systemic radiotherapy, monoclonal antibodies, antiangiogenic therapy, insulin-like growth factor-1 receptor inhibitors, aurora kinase A inhibitor, several ALK inhibitors and multikinase inhibitor sunitinib [49, 50]. Frequent treatment failure in HR NBL is due to drug resistance that occurs in the majority of patients who initially responded well to chemotherapy. The necessity to develop new treatment modalities for HR NBL is indisputable.

Cellular heterogeneity is a feature of human NBL tumors and cell lines and it correlates with clinical behavior. These properties have been used for the classification and prognosis of the disease. The same cellular heterogeneity is manifested in cell lines derived from these tumors. Three distinct cellular phenotypic variants in human neuroblastoma cell lines have been identified: (i) neuroblastic (N type), the most common type, grows as poorly attached aggregates of small rounded cells when grow in the culture [51]. I type resembles non-neuronal precursor cells, as these large flattened cells attach strongly to the substrate and show contact inhibition in their growth pattern; (iii) 1 type represents a more primitive cell type, a progenitor of N- or S-type. I type shows intermediate characters and morphology in between N and S types. They are small, flattened, moderately adherent cells, with or without neuritic processes. Cells of this type form aggregates when grow in the culture [51].

Studies investigating malignant potential of human NBL cell lines showed that I-type cell lines are the most tumorigenic ones. Stem cells derived from I type have more ability to differentiate into different cell types than other types, having a high colony-forming capacity and high growth potential in immunodeficient mice. It has been proved that malignant stem cell phenotype (CD133 and c-kit expression), but not MYCN amplification status or its expression, defines the tumorigenic potential of the various NBL cell lines [52]. Those results were also proved by examination of 40 tumor samples which showed that percentage of CD133+ cells was higher in neuroblastoma than in ganglioneuroblastoma, correlated with clinical stage, and was higher in tumors with unfavorable than favorable histology. In addition, the median survival time of patients with CD133- tumors was longer than those with CD133+ ones [53]. The question arises, whether the presence of CD133+ cells is an independent prognostic marker or it only correlates with other prognostic markers such as histology or the clinical stage. Knockdown of CD133 inhibits differentiation of NBL cell lines and primary tumor cells, which is dependent on RET tyrosine kinase expression. Inhibition of CD133 using siRNA increases RET expression in NBL cells. RET repression and NBL differentiation are caused by activation of p38MAPK or PI3K/Akt pathways [54]. CD133 knockdown inhibits sphere formation in NBL cell line suggesting that CD133 appears to have a role in tumor cell stemness in NBL [55].

Only NBL stage 4–derived cells generate spheres, however the MYCN expression status was not related to the sphere forming ability. The sphere-forming cells, selected from the highly malignant NBL tumor samples are resistant to doxorubicin, cisplatin and etoposide compared to cells cultivated in medium with serum. Average CD133 expression was also increased in spheres but not in every analyzed sphere derived from NBL samples and cell lines [56]. This finding doubts the significance of CD133 as an universal marker of all CSCs in NBL and shows that is unreliable to detect CSCs using a single marker.

Hansford et al. (2007) studied tumor-initiating capacity of cells from bone marrow metastasis of NBL. They found that NBL cells, both HR and LR isolated from bone marrow metastases and grew as spheres in a serum-free medium, were self-renewing and have chromosomal aberrations typical for NBL [57]. Cells from spheres that were derived from HR NBL had higher self-renewal capacity than those from low-risk NBL. Even only 10 cells isolated from HR NBL derived spheres were able to induce tumors that metastasize in an orthotopic mouse model. Those data indicate that NBL contains CSCs and that those cells have metastasizing potential [57]. The differences between possibility of LR NBL cells to form spheres which were described by Coulon and Hansford might be explained by source of the cells. Hansford et al examined cells isolated from bone marrow metastases and those cells form spheres regardless of the risk group. While Coulon et al. used isolated cells from primary tumors that had grown as spheres only when they were derived from HR NBL [56].
NBL CSCs have a different genetic profile than „non-stem tumor cells” in NBL cell lines and in tumors. Cournoyer et al found using the Affymetrix Genome-Wide Human SNP Array 6.0 that CD133+ cells isolated from six NBL cell lines have gains on 16p13.3, 19p13.3, and 19q13.33 that are absent in CD133- cells. There was correlation between the presence of a gain of 16p13 and the expression of CD133 in 26 samples of NBL [58].

Other property of NBL CSC that seems to be clinically significant is telomerase activity. Telomere – repetitive sequences of DNA at the ends of chromosomes protect them from degradation. Because of the end-replication problem, telomeres become shorter, with each cellular division resulting in cellular senescence. Immortal cells e.g. germ cells, stem cells, and memory lymphocytes are thought to maintain telomeres for self-renewal through reactivation of the telomerase. This is a complex ribonucleoprotein composed in part of telomerase RNA (TR) and the telomerase reverse transcriptase. 90% – 95% of human cancers maintain their telomeres through telomerase activation. Spontaneous regression of low risk NBL was found in tumors that lack telomerase activity. Castelo-Branco et al found that telomerase activity is not a property of all glioblastoma and NBL tumor cells but rather confined only to the CSC subpopulation and is not detectable in the majority of cancer cells. Furthermore, normal tissue stem cells lack telomerase activity and therefore are insensitive to telomerase inhibition, which is a highly specific and effective anti-CSC therapy. Furthermore, as opposed to conventional chemotherapies, telomerase inhibition resulted in CSC exhaustion by irreversibly altering their self-renewal capacity [59].

Smith KM et al. identified compounds that selectively targeted NBL cells with CSC properties while having little effect on normal stem cells. They found two compounds – dequallinium analogue (DECA-14) and rapamycin, that prevent CSC self-renewal both in vitro and in vivo. This difference suggest that CSC in NBL play important role in metastases development [60].

Chemoresistance of NBL CSCs. CD133+ cells from different cancers are chemoresistant and have been enriched in vivo after treatment with cisplatin, etoposide, doxorubicin, and paclitaxel [19, 43].

The NBL derived side population was capable of sustained expansion in vitro and demonstrated asymmetric division. The side population cells expressed high levels of ABCG2 and ABCA3 transporter genes and had capacity to expel mitoxantrone, resulting in better survival of side population cells during cultivation with this cytostatics [61]. ABCG2 (known also as breast cancer resistance protein – BCRP) transport not only mitoxantrone but also anthracycline cytostatics, imatinib and topoisomerase I and II inhibitors.

The CD133+ cells isolated from NBL, osteosarcoma and Ewing sarcoma cell lines showed to be more resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones. Furthermore, a decrease in apoptosis was observed in CD133+ cells after incubation with above mentioned cytostatics. CD133+ NBL SK-NSH cells expressed less MKP-1 and more phosphorylated forms of both ERK and P-38 kinases [62]. Mitogen-activated protein kinases (MAP kinases) influence cell-cycle progression, differentiation and cell death. The differential expression of some MAP kinases such as P-38, JNK, ERK, and P13Kr significantly influences cell death. Omichi et al described that DNA damage caused by cisplatin activated JNK and ERK cascades in different ways, and their inhibition sensitized cancer cells to cisplatin [63]. MKP-1 dephosphorylates ERK, JNK, and P-38 in the cell nucleus [64]. Therefore higher expression of MKP-1 in CD133- cells is related to increase dephosphorylation of P-38 and ERK seen in those cells. This phenomenon might explain one of the mechanisms of chemoresistance in CSCs of NBL [62]. The significance of CSCs in tumor recurrence caused presumably by chemoresistance was confirmed by Newton et al. These authors found that the size of the side population in cell lines established from recurrent tumors was increased compared to its paired pretreatment cell line [65]. In addition, the side population cells from recurrent NBLs showed an increased proliferation, and were more coloniforming [65].

Epigenetical influencing of CSCs. Being resistant to chemotherapy, there were many attempts to target CSCs epigenetically. Valproic acid (VPA) has been used for treatment of epilepsy since the 1970s and it was demonstrated that it also inhibits histone deacetylases (HDAC). Recently, this drug has been tested in differentiation therapy of AML and MDS [66]. In contrast to the experiments, which show that VPA caused differentiation in AML, it found to increase the percentage of normal haematopoietic stem cells (HSC) more than in differentiated cells. In in-vivo experiments VPA increased the capability of HSC to repopulate bone marrow of lethal irradiated mice [67]. VPA exhibits different effects on normal haematopoietic stem cells than on the leukemic blasts. There is a relationship between differentiation and the response to VPA. Immature cells respond with a down-regulation of p21cip-1/waf-1 that cause progression of cell cycle, while more differentiated cells respond with its down-regulation that will induce differentiation or apoptosis. The explanation for these phenomena is that VPA increases self-renewal of HSC probably by the inhibition of GSK3h through its phosphorylation that activates Wnt signaling pathway. Wnt signaling is important for the self-renewal property of stem cells [67]. Both experimental and clinical studies showed that VPA potentiates the effect of various cytostatics that is explained by the enhancement of apoptosis, the up-regulation of p21cip-1/waf-1 expression and/or the impact of HDAC inhibitors on chromatin structure. HDAC inhibitors facilitate decondensation of chromatin by increasing the acetylation of several histones, hence relaxed chromatin is more sensitive to ionizing radiation and DNA-damaging agents. They also reduce double strand break repair capacity [66]. The data that show the diverse influence of VPA on normal and cancer stem cells seem to be very important for clinical practice. VPA in nontoxic concentrations sensitized the adherent or differentiated breast cancer cells (primocultures
and cell lines) to ionizing radiation that were monitored using clonogenic assay but not CSCs as evaluated by sphere formation assay. Unlike the effect on more differentiated cancer cells, VPA had a radioprotective effect on CSCs. These facts were approved by results found in in-vitro experiments showing that VPA may increase CSCs after radiotherapy [68].

Decitabine (a methyltransferase inhibitor) or trichostatin A (an HDAC inhibitor) induced an increase in surface expression of CD133 in the selected CD133- ovarian cancer cells. Combination of both drugs had synergistic effect on CD133 expression. The explanation of this phenomenon may be that DNA methylation silences CD133 expression and that histone deacetylation influences regulation of the CD133 promotor [69]. Recently, we have found an increase in percentage of CD133+ NBL cells after their incubation with VPA in a dose that did not induce apoptosis [45] (see Fig 4). We showed that VPA induced death in NBL cells growing both under normoxic and hypoxic conditions and can overcome hypoxia induced resistance to cisplatin-induced apoptosis in HR NBL cells [70]. However, the question remains whether those changes are connected with hypoxic induction of CSCs, or whether VPA affects only more differentiated cells.

Until now, our knowledge is still limited to consider HDAC inhibitors as CSCs targeted therapy.

**Future directions.** CSCs are one of the most intensively studied topics in current oncology. More than 35,000 articles are found in PubMed, when using the key words “cancer stem cell". However we are missing the basic information which is necessary for further research on CSCs and clinical application for their detection in diagnostics and CSC target therapy. It is necessary to: (i) define the CSC function in cancerogenesis, cancer development and their role in metastasis and chemoresistance; (ii) find a specific marker for CSCs in certain tumors; (iii) explain the role of different pathways that determine their behavior and (iv) resolve mechanisms of chemoresistance of CSCs [2, 7, 8, 17, 56].

Acknowledgments: This study was supported by grant GACR P301/10/0356 and by the project for conceptual development of research organization 00064203.

**References**


[35] BRUNO S, BUSSOLATI B, GRANGE C, COLLINO F, GRAZIANO ME et al. CD133+ renal progenitor cells contrib-
CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007; 117, 455–460. http://dx.doi.org/10.1097/01.mlg.0000251856.15299.35


[65] NEWTON TC, WOLCOTT K, ROBERTS SS. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl Oncol 2010; 3, 246–251.


